Japan Pharma - Top Picks
While Gni Group Ltd (2160 JP) is our high risk-high return pick, Mitsubishi Tanabe Pharma (4508 JP) is a contrarian call in anticipation of value...
543 Views
SymBio Pharmaceuticals - Preparing to establish own sales organisation
SymBio announced in October that it has begun preparations to establish its own sales organisation to market Treakisym and other anticancer drugs...
38 Views
Japan Fortnightly Update: Spiked
SHORT-LIVED - The much-lauded 'breakout' in the Nikkei 225 (NKY INDEX) at the end of last month proved to be short-lived. As measured by Total...
347 Views
Symbio Confirms Treakisym’s In-House Commercialization Post Patent Expiration in 2020e
Significantly reduces execution risk for an operational turnaround in 2021e As highlighted in previous notes ("Symbio Pharma (4582 JP) - Gross...
258 Views
Smartkarma’s Week that Was in JP/KR: King Street Vs. Toshiba, Korea's Donki, and SKT Split
Below is the list of the Japan/Korea related posts put on the Smartkarma platform last week. It was a holiday week for both Japan and Korea. So, we...
354 Views